Page last updated: 2024-11-02

pipobroman and Leukemia

pipobroman has been researched along with Leukemia in 14 studies

Pipobroman: An antineoplastic agent that acts by alkylation.
pipobroman : An N-acylpiperazine that is piperazine in which each of the nitrogens has been acylated by a 3-bromopropionoyl group. An anti-cancer drug.

Leukemia: A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)

Research Excerpts

ExcerptRelevanceReference
"From 1968 to 1993, 179 newly diagnosed patients with polycythemia vera (PV) were enrolled in a prospective study using pipobroman as first chemotherapy."9.10Long-term outcomes of polycythemia vera patients treated with pipobroman as initial therapy. ( Bernard, JF; Bruno, F; Gardin, C; Kiladjian, JJ; Renoux, M, 2003)
" All patients received PB at the dosage of 1 mg/kg/day until response was achieved (hematocrit value <50% in males and <45% in females)."5.30Polycythemia vera treated with pipobroman as single agent: low incidence of secondary leukemia in a cohort of patients observed during 20 years (1971-1991). ( Avvisati, G; Cosenza, M; Latagliata, R; Malagnino, F; Montefusco, E; Petti, MC; Spadea, A; Spadea, T, 1998)
"From 1968 to 1993, 179 newly diagnosed patients with polycythemia vera (PV) were enrolled in a prospective study using pipobroman as first chemotherapy."5.10Long-term outcomes of polycythemia vera patients treated with pipobroman as initial therapy. ( Bernard, JF; Bruno, F; Gardin, C; Kiladjian, JJ; Renoux, M, 2003)
"The risk of major thrombosis is higher in ET patients aged more than 60 ys."2.39Treatment strategies in essential thrombocythemia. A critical appraisal of various experiences in different centers. ( Barbui, T; Brière, J; Dupuy, E; Finazzi, G; Kiladjian, JJ, 1996)
" All patients received PB at the dosage of 1 mg/kg/day until response was achieved (hematocrit value <50% in males and <45% in females)."1.30Polycythemia vera treated with pipobroman as single agent: low incidence of secondary leukemia in a cohort of patients observed during 20 years (1971-1991). ( Avvisati, G; Cosenza, M; Latagliata, R; Malagnino, F; Montefusco, E; Petti, MC; Spadea, A; Spadea, T, 1998)
" Relapses occurred in 30% of the cases but responded to pipobroman at the initial high dosage level."1.26[Management of polycythaemia with pipobroman]. ( Duhamel, G; Gorin, NC; Najman, A; Parlier, Y; Perreau-Boutet, MC; Stachowiak, J, 1982)

Research

Studies (14)

TimeframeStudies, this research(%)All Research%
pre-19902 (14.29)18.7374
1990's4 (28.57)18.2507
2000's8 (57.14)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Kiladjian, JJ3
Gardin, C1
Renoux, M1
Bruno, F1
Bernard, JF2
De Sanctis, V1
Mazzucconi, MG1
Spadea, A2
Alfò, M1
Mancini, M1
Bizzoni, L1
Peraino, M1
Mandelli, F1
Passamonti, F1
Rumi, E1
Malabarba, L1
Arcaini, L1
Orlandi, E1
Brusamolino, E1
Pascutto, C1
Cazzola, M1
Lazzarino, M1
Rain, JD2
Briere, J3
Chomienne, C1
Fenaux, P1
Perreau-Boutet, MC1
Najman, A1
Stachowiak, J1
Parlier, Y1
Gorin, NC1
Duhamel, G1
Boivin, P1
Barbui, T1
Finazzi, G1
Dupuy, E1
Petti, MC1
Avvisati, G1
Spadea, T1
Latagliata, R1
Montefusco, E1
Cosenza, M1
Malagnino, F1
Pearson, TC1
Green, AR1
Reilly, JT1
Harrisoni, G1
Randi, ML1
Fabris, F1
Girolami, A1
Lengfelder, E1
Hehlmann, R1
Guilmin, F1

Reviews

4 reviews available for pipobroman and Leukemia

ArticleYear
Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia.
    Seminars in thrombosis and hemostasis, 2006, Volume: 32, Issue:4 Pt 2

    Topics: Antineoplastic Agents, Alkylating; Drug Therapy, Combination; Female; Humans; Hydroxyurea; Interfero

2006
Treatment strategies in essential thrombocythemia. A critical appraisal of various experiences in different centers.
    Leukemia & lymphoma, 1996, Volume: 22 Suppl 1

    Topics: Adult; Aged; Alkylating Agents; Anemia, Megaloblastic; Arrhythmias, Cardiac; Bone Marrow Diseases; B

1996
[Polycythemia vera: current status of therapy].
    Deutsche medizinische Wochenschrift (1946), 2000, Oct-13, Volume: 125, Issue:41

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Bloodletting; Clinical Trials

2000
Management of patients with essential thrombocythemia: current concepts and perspectives.
    Pathologie-biologie, 2001, Volume: 49, Issue:2

    Topics: Adult; Aged; Aspirin; Case Management; Clinical Trials as Topic; Diagnosis, Differential; Disease Pr

2001

Trials

2 trials available for pipobroman and Leukemia

ArticleYear
Long-term outcomes of polycythemia vera patients treated with pipobroman as initial therapy.
    The hematology journal : the official journal of the European Haematology Association, 2003, Volume: 4, Issue:3

    Topics: Actuarial Analysis; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Cause of Deat

2003
Indications, procedure and results for the treatment of polycythaemia vera by bleeding, pipobroman and hydroxyurea.
    Nouvelle revue francaise d'hematologie, 1993, Volume: 35, Issue:5

    Topics: Acute Disease; Bloodletting; Combined Modality Therapy; Humans; Hydroxyurea; Leukemia; Phosphorus Ra

1993

Other Studies

8 other studies available for pipobroman and Leukemia

ArticleYear
Long-term evaluation of 164 patients with essential thrombocythaemia treated with pipobroman: occurrence of leukaemic evolution.
    British journal of haematology, 2003, Volume: 123, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Alkylating Agents; Disease Progression; Female; Humans; Leukemia; Ma

2003
Long-term follow-up of young patients with essential thrombocythemia treated with pipobroman.
    Annals of hematology, 2004, Volume: 83, Issue:8

    Topics: Adult; Cause of Death; Drug Evaluation; Female; Humans; Incidence; Leukemia; Longitudinal Studies; M

2004
[Management of polycythaemia with pipobroman].
    La Nouvelle presse medicale, 1982, Sep-04, Volume: 11, Issue:34

    Topics: Female; Humans; Leukemia; Male; Myeloproliferative Disorders; Pipobroman; Polycythemia; Polycythemia

1982
Polycythemia vera treated with pipobroman as single agent: low incidence of secondary leukemia in a cohort of patients observed during 20 years (1971-1991).
    Leukemia, 1998, Volume: 12, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Cohort Studies; Female; Follow-Up

1998
Leukemic transformation in polycythemia Vera. MPD(UK) Study Group.
    Blood, 1998, Sep-01, Volume: 92, Issue:5

    Topics: Antineoplastic Agents; Humans; Hydroxyurea; Leukemia; Pipobroman; Polycythemia Vera

1998
Leukemia and myelodysplasia effect of multiple cytotoxic therapy in essential thrombocythemia.
    Leukemia & lymphoma, 2000, Volume: 37, Issue:3-4

    Topics: Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Busulfan; Fatal Outcome; Female; Humans; Hydro

2000
[Hydroxyurea--is it a harmless drug in Vaquez disease?]].
    Pathologie-biologie, 2001, Volume: 49, Issue:2

    Topics: Aged; Alopecia; Combined Modality Therapy; Cystitis; Erectile Dysfunction; Female; Fever; Follow-Up

2001
Drugs in the treatment of leukemia.
    British medical journal, 1968, Nov-02, Volume: 4, Issue:5626

    Topics: Asparaginase; Busulfan; Chlorambucil; Cyclophosphamide; Cytarabine; Humans; Hydroxyurea; Leukemia; L

1968